[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depression-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depression-severe":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631616","phase-1-shortened-lsd-intervention-for-major-depressive-disorder-100631616",false,"NCT07503002","Shortened LSD Intervention for Major Depressive Disorder","SLIM","Inclusion Criteria:\n\n* Have given written informed consent\n* Meet DSM-5 criteria for MDD\n* MADRS \\>= 28 at screening Can read, write, and speak English fluently\n* Be judged by study team clinicians to be at low risk for suicidality\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing, or not practicing an effective means of birth control\n* Cardiovascular conditions: hypertension with resting blood pressure systolic \\>139 or diastolic \\>89, angina, heart rate \\> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \\> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy\n* Epilepsy\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Currently taking antipsychotics, or MAO inhibitors\n* Patients taking antidepressant medications and unable to taper\n* Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment\n* Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered\n* Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag\n* Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition\n* Morbidly obese (\\>100 lbs. above ideal body weight, or BMI \\>=40, or BMI \\>=35 with high blood pressure or diabetes)\n* Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal\n* Body weight \\\u003C 45 kg\n* Significant acute adverse reaction (e.g., dystonia) to an antipsychotic\n* Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major\n* Depression with psychotic features\n* Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.","ALL","21 Years","70 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.",[27,28,29],"Major Depression Moderate","Major Depression Severe","Major Depression",[31,32,33,34,35,36],"LSD","lysergic acid diethylamide","depression","MDD","major depression","major depressive","NOT_YET_RECRUITING","2026-03-30",{"date":40,"type":41},"2026-04-03","ACTUAL",{"date":43,"type":21},"2026-07-01",{"date":45,"type":21},"2027-12-01",{"name":47,"class":48},"Johns Hopkins University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":74,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":49},"100573643","ketogenic-metabolic-therapy-in-schizophrenia-bipolar-disorder-major-depressive-disorder-deep-omic-profiling-100573643","NCT06748950","Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","A Randomized Controlled Trial of a Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","Inclusion Criteria:\n\n1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia\n\n   1. For individuals diagnosed with bipolar disorder (BD):\n\n      * Meet DSM V criteria for BD (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n   2. For individuals diagnosed with major depressive disorder (MDD):\n\n      * Not mild\n      * PHQ-9 \\> 10\n      * clinically stable (with no hospitalization for past 3 months)\n   3. For individuals diagnosed with schizophrenia:\n\n      * Meet DSM V criteria for schizophrenia (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n2. Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medication. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least four weeks prior to screening and if it is expected to remain stable. Participants may be switched from other classes of medication to another medication class by their psychiatrist or primary care doctor, but need to be stable enough to enroll and adhere to study procedures.\n3. willing and able to give informed consent for participation in English.\n4. live within the United States.\n\n   \\--------------------------------------------------------------------------------\n\nExclusion Criteria:\n\n1. has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll\n2. pregnant or nursing\n3. insulin dependent\n4. comorbidity of developmental delay\n5. in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary programs.\n6. any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months\n7. inability to complete baseline measurements\n8. severe renal or hepatic insufficiency\n9. cardiovascular dysfunction, including diagnosis of:\n\n   * Congestive heart failure\n   * Angina\n   * Arrhythmias\n   * Cardiomyopathy\n   * Valvular heart disease\n10. active substance abuse with illicit drugs or alcohol and\u002For current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine or cannabis dependence\n11. active suicidal and considered at significant risk for suicide during course of study\n12. participation in any clinical trial- within the past month or concurrent to study participation- with an investigational drug\u002Fdevice and\u002For intervention that may interfere with study participation\u002Fevaluation of results\n13. mild BPRS at screening or baseline visits\n14. history of TBI\n15. any other medical condition that may make diet intervention dangerous as determined by the study medical team (e.g. anorexia nervosa) or assessed by study team to have insufficient control over their food intake to adhere to study diets.\n16. any medical condition that physicians or the PI believe would interfere with study participation or evaluation of results\n17. history of familial hypercholesterolemia","18 Years","80 Years",{"count":60,"type":21},120,[62],"NA","The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.",[65,66,67,68,69,28,70,71,72,73],"Schizophrenia","Schizophrenia and Related Disorders","Bipolar Disorder","Bipolar and Related Disorders","Major Depressive Disorder","Ketogenic Dieting","Ketosis","Metabolic Disease","Metabolic Syndrome",[75,76,77,78],"Mental Illness","Multiomics","Multi-omics","Omics Profiling","2025-05-13",{"date":81,"type":41},"2025-05-16",{"date":83,"type":21},"2025-07",{"date":85,"type":21},"2028-07",{"name":87,"class":48},"Stanford University"]